Показано 0 из 0
Дата |
---|
18:17 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.70
|
4.76
|
4.60
|
4.60
|
4.74
|
4.70
|
|
|
19 406.74
|
104.00
|
4.34
|
4.89
|
4.72
|
4.46
|
4.775
|
4.63
|
|
|
134 864.88
|
710.00
|
2.05
|
11.00
|
4.30
|
4.22
|
4.44
|
4.355
|
|
|
36 672.48
|
245.00
|
4.06
|
4.64
|
4.27
|
3.92
|
4.27
|
4.12
|
|
|
54 538.14
|
216.00
|
3.63
|
11.00
|
4.68
|
4.22
|
4.88
|
4.28
|
|
|
60 666.31
|
233.00
|
4.50
|
4.87
|
4.39
|
4.34
|
4.84
|
4.65
|
|
|
189 607.85
|
482.00
|
4.25
|
4.50
|
3.70
|
3.70
|
4.80
|
4.40
|
|
|
443 041.88
|
1 294.00
|
3.57
|
3.84
|
3.47
|
3.45
|
3.77
|
3.605
|
|
|
86 467.44
|
347.00
|
3.67
|
3.73
|
3.44
|
3.15
|
3.49
|
3.31
|
|
|
515 948.51
|
1 611.00
|
3.39
|
3.60
|
3.31
|
3.31
|
3.63
|
3.47
|
|
|
91 187.72
|
297.00
|
Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab.